Comparison of the effects of selective inhibition of thromboxane synthase with those of inhibition of the cyclooxygenase enzyme in man.
D015121:6-Ketoprostaglandin F1 alpha / Q000031:analogs & derivatives / Q000652:urine; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D013997:Time Factors
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D007093:Imidazoles; D011725:Pyridines; C029166:dazoxiben; D016718:Arachidonic Acid; D015121:6-Ketoprostaglandin F1 alpha; C028290:2,3-dinor-6-ketoprostaglandin F1alpha; C037787:pirmagrel; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; D001241:Aspirin